Elsayed Soliman

Conflicts of Interest Dr Elkind reported receiving nonfinancial support from BMS-Pfizer Alliance for Eliquis (study drug in kind for the ARCADIA trial) and grants from Roche (ancillary support for the ARCADIA trial) during the conduct of the study and honoraria from Atria Academy for Science and Medicine and royalties from UpToDate outside the submitted work; Dr Elkind is employed by the American Heart Association. No other disclosures were reported.

CIIS cardiac infarction injury score CVD cardiovascular disease HR hazard ratio NHANES The National Health and Nutrition Examination Survey PIR poverty-income ratio SD standard deviation SES socioeconomic status 1 Introduction Cardiovascular disease (CVD) is a leading cause of death in the United States, with low socioeconomic status (SES) being a recognized contributor to CVD-related morbidity and mortality [1, 2].

Introduction Cardiovascular disease (CVD) is the top cause of death both in the United States (US) and globally (1). It is estimated that 80% of CVD is preventable (2). Conventional CVD prevention strategies emphasize the optimizations of classical risk factors such as blood pressure and lipids. However, it is challenging to communicate CVD risk to young individuals with a low absolute 10-year CVD risk.